To provide some very rough guidance as to possible Phase 3 trial size and cost –
The Phase 3 trial for trofinetide in Rett syndrome had 187 participants.
Soleno’s first Phase 3 trial in PWS had 127 participants.
Acadia’s Phase 3 trial in PWS is enrolling 170 participants.
Harmony Bioscience’s Phase 3 trial in PWS is enrolling 134 participants.
Ultragenyx’s Phase 3 trial in Angelman syndrome will enrol 120 participants.
Note that all these Phase 3 trials are placebo-controlled.
Acadia is currently spending ~US$7m per qtr on its PWS trial and the trial is estimated to run for 10 quarters. Perhaps nudging US$90-100m all up?
Harmony Biosciences is spending US$7-8m per qtr on its PWS trial and is estimated to run for 9 quarters. Possibly similar cost to Acadia to see this through?
To provide some very rough guidance as to possible Phase 3 trial...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
0.000(0.00%) |
Mkt cap ! $1.990B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 141 | $16.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.80 | 335 | 1 |
View Market Depth
| Last trade - 09.49am 19/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable